Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects

被引：0
|
作者：
Chanan Shaul
Simcha Blotnick
Mordechai Muszkat
Meir Bialer
Yoseph Caraco
机构：
[1] Hadassah-Hebrew University Medical Center,Clinical Pharmacology Unit, Division of Medicine
[2] Hebrew University,Institute of Drug Research, School of Pharmacy, Faculty of Medicine
来源：
Molecular Diagnosis & Therapy | 2017年 / 21卷
关键词：
Warfarin; Variant Allele; Warfarin Dose; Oral Clearance; CYP2C9 Genotype;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
  • [21] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [22] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Chanan Shaul
    Simcha Blotnick
    Liat Adar
    Mordechai Muszkat
    Meir Bialer
    Yoseph Caraco
    Clinical Pharmacokinetics, 2022, 61 : 1187 - 1198
  • [23] Warfarin dose requirement and CYP2C9 polymorphisms -: Reply
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    LANCET, 1999, 353 (9168): : 1972 - 1973
  • [24] Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
    Gardin, Anne
    Ufer, Mike
    Legangneux, Eric
    Rossato, Gianluca
    Jin, Yi
    Su, Zhenzhong
    Pal, Parasar
    Li, Wenkui
    Shakeri-Nejad, Kasra
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 349 - 361
  • [25] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Kim, Myong-Jin
    Nafziger, Anne N.
    Kashuba, Angela D. M.
    Kirchheiner, Julia
    Bauer, Steffen
    Gaedigk, Andrea
    Bertino, Joseph S., Jr.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 431 - 436
  • [26] Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
    Anne Gardin
    Mike Ufer
    Eric Legangneux
    Gianluca Rossato
    Yi Jin
    Zhenzhong Su
    Parasar Pal
    Wenkui Li
    Kasra Shakeri-Nejad
    Clinical Pharmacokinetics, 2019, 58 : 349 - 361
  • [27] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Myong-Jin Kim
    Anne N. Nafziger
    Angela D. M. Kashuba
    Julia Kirchheiner
    Steffen Bauer
    Andrea Gaedigk
    Joseph S. Bertino
    European Journal of Clinical Pharmacology, 2006, 62 : 431 - 436
  • [28] Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
    Ruud, Ellen
    Holmstrom, Henrik
    Bergan, Stein
    Wesenberg, Finn
    PEDIATRIC BLOOD & CANCER, 2008, 50 (03) : 710 - 713
  • [29] Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-Warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers
    Ma, JD
    Nafziger, AN
    Kashuba, ADM
    Kim, MF
    Gaedigk, A
    Rowland, E
    Kim, JS
    Bertino, JS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06): : 570 - 576
  • [30] The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
    Taskin, Birce Dilge
    Kula, Serdar
    Ergun, Mehmet Ali
    Altun, Demet
    Olgunturk, Rana
    Tunaoglu, Fatma Sedef
    Oguz, Ayse Deniz
    Gursel, Turkiz
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (10): : 791 - 796
12345